patientboard.com

What It Is

PatientBoard.com positions itself as a Venture Intelligence platform for founders and investors, with the tagline “Smarter ventures. Faster launches.” Based on the information on the page, it is part of the eCorp network and claims to track 20,000+ ventures while currently accepting early members. The public-facing content at this stage feels more like an early product landing page. Its core value proposition is to help users discover opportunities, analyze markets, and move from ideas to launch or investment decisions.

Core Features and Workflow

The product highlights three main modules. The first is Opportunity Intelligence: an AI curated pipeline that filters opportunities using scores, signals, and market context. The second is Automated Diligence, covering financial analysis, market sizing, and risk assessment, with the goal of compressing diligence work into hours. The third is Portfolio Analytics, which provides real-time performance tracking and predictive modeling. The workflow is presented in three steps: import deals from a CRM, network, or manual entry; let AI automatically score, analyze, and benchmark them; and then use data-driven insights to support investment decisions.

Pricing and Enterprise Capabilities

On pricing, the page clearly states that early membership is “Free forever” and “Free to start,” with no credit card required, so the trial barrier is very low. However, it does not disclose formal paid plans, seat limits, data-volume restrictions, or service levels after upgrading. Common enterprise software features such as team collaboration, role-based permissions, audit logs, data security and compliance, APIs, developer documentation, and self-hosted deployment are not mentioned. Third-party integrations are only described broadly as the ability to import from any CRM, without listing specific supported platforms such as Salesforce or HubSpot.

Pros, Cons, and Who It’s For

Its main advantage is that it covers the full front-end workflow for investment firms, from deal sourcing and automated diligence to portfolio monitoring, while the free early-access model lowers the cost of trying it. The downside is that public information is still very limited: there are no customer case studies, real product screenshots, explanations of data sources, or security and compliance commitments. The page is also somewhat repetitive, and its maturity and delivery capability still need to be validated. It is best suited for early adopters such as angel investors, small VC teams, startup incubation teams, and founders who need to quickly screen market opportunities.

Access from China and Alternatives

The page does not disclose access conditions from China, so network connectivity, Chinese-language support, and domestic payment options are unclear. At present, it only states that users can join the early list without a credit card. Teams in China should first verify access stability, whether the data coverage includes the Chinese market, and whether the product meets local compliance requirements. Comparable alternatives include Crunchbase, Dealroom, PitchBook, CB Insights, as well as China-focused platforms such as IT桔子 and 烯牛数据.